作者
Luis Paz-Ares, E-H Tan, Ken O’Byrne, L Zhang, Vera Hirsh, M Boyer, JC-H Yang, T Mok, KH Lee, S Lu, Y Shi, DH Lee, J Laskin, D-W Kim, SA Laurie, K Kölbeck, J Fan, N Dodd, A Märten, K Park
发表日期
2017/2/1
期刊
Annals of Oncology
卷号
28
期号
2
页码范围
270-277
出版商
Elsevier
简介
Background
In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data.
Patients and methods
LUX-Lung 7 assessed afatinib 40 mg/day versus gefitinib 250 mg/day in treatment-naïve patients with stage IIIb/IV NSCLC and a common EGFR mutation (exon 19 deletion/L858R). Primary OS analysis was planned after ∼213 OS events and ≥32-month follow-up. OS was analysed by a Cox proportional hazards model, stratified by EGFR mutation type and baseline brain metastases.
Results
Two-hundred and twenty-six OS events had occurred at the data cut-off (8 April 2016). After a median follow-up …
学术搜索中的文章
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of Oncology, 2017